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Abstract 
Leishmania are obligate intracellular parasites that cause a wide spectrum of diseases ranging 
from cutaneous, mucocutaneous and the visceral kind. Persistence or resolution of leish-
maniasis is governed by host immune response. Co-stimulation is an important secondary 
signal that governs the extent, strength and direction of the immune response that follows. 
Co-stimulation by CD40, B7 and OX40 family has been shown to influence the outcome 
following Leishmania infection and manipulation of these pathways has shown promise for use 
in immune therapy of leishmaniasis. In this review, we discuss the roles of CD40, B7 and 
OX40 co-stimulatory pathways in regulating immunity to Leishmania and their implications in 
the treatment of this disease. 
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Leishmaniasis 
The genus Leishmania comprises of obligate in-
tracellular  parasites  which  are  released  into  the 
bloodstream of their vertebrate host when an infected 
vector sand fly takes a blood meal thereby injecting 
promastigote  form  of  the  parasite  [1].  The  pro-
mastigotes are taken up by a variety of immune cells 
early on, like neutrophils  and dendritic cells (DCs). 
The parasites eventually gain entry into their natural 
host cell, the macrophages, where they differentiate 
into intracellular amastigotes [2]. Then on, the inter-
play between host’s innate and adaptive immune cells 
and the resultant cytokines released ultimately skew 
the immune response towards either disease resolu-
tion  or  persistence.  The  range  of  clinical  manifesta-
tions of leishmaniasis is documented broadly as cu-
taneous  leishmaniasis  (CL),  caused  by  L.  major,  L. 
tropica  and  L.  mexicana,  the  mucocutaneous  leish-
maniasis (MCL), caused by L. braziliensis and visceral 
leishmaniasis (VL), caused by  L. donovani and L. in-
fantum (chagasi) [1]. World over, 12 million people are 
estimated to be infected with leishmaniasis and 350 
million  people  are  potentially  at  risk  of  acquiring 
leishmaniasis [3]. 
Long term immunity to CL is governed by de-
velopment of an effective adaptive immune response 
where T helper cells play a crucial role. Induction of T 
helper phenotype 1 (Th1) is associated with produc-
tion  of  proinflammatory  cytokines  IFN-γ  and  IL-12 
while  Th2  cells  predominantly  produce  the  immu-
nosuppressive  cytokines  IL-4  and  IL-10.  IFN-γ  in-
duces production of leishmanicidal nitric oxide (NO) 
from  macrophages  [4-6]  while  IL-12  indirectly  aids 
this pathway by inducing IFN-γ from natural killer 
(NK) and T cells. IL-4 and IL-10 on the other hand 
catalyze arginase activity over inducible nitric oxide 
synthase  (iNOS)  preventing  the  production  of  NO. 
The disease exacerbating role of Th2 vs. resolving role 
of  Th1  cytokines  has  been  well  established  in  CL 
models with L. major. BALB/c mice are predisposed to 
generation  of  Th2  cells  following  L. major  infection 
and hence are highly susceptible while C57BL/6 mice 
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produce  Th1  cells  following  CL  and  have  a  better 
prognosis [7, 8]. 
Compared to CL  model of leishmaniasis by  L. 
major,  where  a  defined  disease  exacerbating  role  of 
Th2 response is noted; in VL, the absence of disease 
resolving  Th1  response  is  related  to  the  severity  of 
infection [9]. 
Co-stimulation 
Effective  long  term  immunity  against  antigens 
requires  activation  of  adaptive  arm  of  immune  re-
sponse  mediated  by  T  lymphocytes.  Antigen  pre-
senting cells (APC) such as DCs, macrophages and B 
cells present processed antigenic peptides via major 
histocompatibility complex (MHC) to T cell receptor 
(TCR) of naïve T cells. The presentation of antigens by 
APC provides the first signal for T cell activation. This 
interaction determines the specificity of the immune 
response.  However,  antigenic  stimulation  in  itself 
cannot  activate  T  cells  effectively  unless  a  second 
signal is received by the cells. Ligands on APCs called 
co-stimulatory  molecules  interact  with  specific  re-
ceptors on T cells providing the second signal which 
then leads to activation of the antigen stimulated T 
cell [10, 11]. 
A  number  of  co-stimulatory  pathways  are  in-
volved in mediating T cell responses. Co-stimulation 
is critical not only for activation but also inhibition 
and  often  acts  in  a  spatial  manner  wherein  certain 
pathways come into play during priming and others 
during  the  effector  stages  of  infection  or  memory 
generation [10]. In this review we take a closer look at 
some of the co-stimulatory pathways involved in the 
modulation of Leishmania infection. 
The CD40 family 
The CD40 receptor is a Type I transmembrane 
receptor phosphorylated glycoprotein that consists of 
an  extracellular  carboxy  terminal  segment  with  22 
cysteine residues, homologous to other members of 
the tumor necrosis receptor family (TNRF). It is found 
ubiquitously  on  the  surface  of  monocytes,  macro-
phages, DCs as well as non-immune cells such as ep-
ithelial cells and platelets [12-14]. CD40L, the ligand 
for CD40 receptor protein is a Type II transmembrane 
protein that exists as a homotrimer. CD40L is primar-
ily present on the surface of activated mature T cells 
as well as non resting T cells. It is mostly present on 
CD4+ T cells although a small population of CD8+ T 
cells also possesses this antigen. Other immune cells 
such as eosinophils, basophils and mast cells are also 
known to possess CD40L while it is only expressed 
under  certain  conditions  by  B  cells,  DCs,  NK  cells, 
monocytes and macrophages [12].  
CD40:CD40L signaling 
CD40:CD40L interaction results in the activation 
of  protein  tyrosine  kinases  (like  lyn,  syk  and  Jak3), 
phosphoinositide-3-kinase  and  phospholipase  CG2. 
Other  studies  have  also  discovered  the  interplay  of 
serine/threonine kinases like JNK/SAPK (c-jun ami-
no  terminal  kinase/stress  activated  protein  kinase), 
p38MAPK  (mitogen-activated  protein  kinase)  and 
ERK (extracellular signal regulated mitogen-activated 
protein  kinase)  [15-17].  Further,  certain  cytoplasmic 
adaptor  proteins  called  TRAFs  (TNF-R  associated 
factors) are recruited to the cytoplasmic tail of CD40 
and this process is enhanced by receptor oligomeriza-
tion. All TRAF proteins, with the exception of TRAF 1, 
have zinc finger domain that are predicted to aid in 
binding DNA or enhance protein-protein interaction. 
This allows the TRAF proteins to participate  in the 
activation of a variety of protein kinases, like the MAP 
kinase family (JNK, ERK and p38MAPK) [15, 16]. The 
existence of CD40 receptors on distinct ‘signalosomes’ 
have been shown in human monocyte-derived DCs 
where the CD40 receptor is constitutively associated 
with cholesterol and sphingolipid rich microdomains 
in the plasma membrane called lipid rafts or mem-
brane rafts. This ordered liquid structure provides a 
platform for CD40 signaling events. There is evidence 
to support that CD40 receptor engagement by anti-
body treatment or association with CD40L results in 
phosphorylation of Lyn tyrosine kinase which is as-
sociated with the membrane rafts. Further, the pres-
ence of Syk tyrosine kinase specifically in the deter-
gent-soluble fractions of membrane extract compared 
to  the  presence  of  CD40  receptor  and  Lyn  tyrosine 
kinase in the detergent-resistant fractions indicates a 
possible  spatial  and  temporal  regulation  of  CD40 
signaling  cascade  where  membrane  bound  Lyn  un-
dergoes phosphorylation first followed by Syk. Other 
proteins  that  were  found  to  constitute  the  CD40 
signalosome were TRAF 2 and TRAF 3 and were re-
cruited to the CD40 cytoplasmic tail following recep-
tor engagement [15]. 
Role of CD40:CD40L interactions in leish-
maniasis 
Early studies on CD40:CD40L interactions have 
identified  key  role  of  this  interaction  in  the  estab-
lishment of effective humoral response, with particu-
lar involvement in immunoglobulin (Ig) isotype class 
switching,  memory  cell  maturation  and  germinal 
center formation. Recent studies have begun to shed 
light on the importance of CD40:CD40L interactions 
in cell mediated immunity [12-14]. CD40 ligation me-
diates  upregulation  of  various  co-stimulatory  mole-Int. J. Biol. Sci. 2011, 7 
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cules, B7-1 and B7-2 in APCs and CD58 in DCs [18], 
apoptosis regulation in CD4+ T cells [19] and produc-
tion of various cytokines amongst which IL-12 pro-
duction by DCs [20] is important during Leishmania 
infection [21, 22]. With particular relevance to Leish-
mania  infections,  CD40  interactions  are  involved  in 
macrophage activation, IL-12 production in DCs and 
CD4+ T cell priming. 
The  protective  role  of  CD40  has  been  demon-
strated in footpad infection model on CD40 deficient 
mice  infected  with  L.  major.  The  CD40-/-  mice  pre-
sented  with  rapid  systemic  development  of  leish-
maniasis compared to the susceptible BALB/c control 
mice.  A  polarized  Th2  response  was  noted  in  the 
CD40-/- mice as indicated by excessive IL-4 levels (at 
values similar to a Th2 skewed response in BALB/c 
mice) and lower levels of IFN-γ production by cells of 
the draining lymph nodes [23]. A similar pattern of 
low  IFN-γ,  tumor  necrosis  factor  (TNF),  and  NO 
production  and  high  IL-4  production  was  seen  in 
CD40L deficient mice infected with L. mexicana [24]. 
This is indicative of impaired T cell mediated macro-
phage activation which results in high parasite tissue 
burden. Although, it has been shown that IFN-γ is a 
potent activator of macrophage activity  [25, 26], in-
fected macrophages treated with IFN-γ alone are un-
able to clear parasites effectively. The addition of an-
ti-CD40 antibody (Ab) was found to be an important 
priming  signal  for  macrophages  resulting  in  lower 
parasite count when used in conjunction with IFN-γ 
treatment as compared to the use of either treatment 
separately.  Hence,  CD40:CD40L  interaction  may  be 
important  in  vivo  for  macrophage  activation  and 
parasite clearance [23].  
IL-12, an important cytokine for generating Th1 
response  [22]  during  Leishmania  infections  [27]  has 
recently been shown in CL and VL models to be pre-
dominantly produced by DCs and not macrophages 
[27-30]. Though a decrease in production of IL-12 in 
CD40 deficient mice was  not directly related to the 
absence of CD40:CD40L interaction [23], a study on 
IL-12  production  in  DCs  infected  with  L. major  has 
shown that this event is dependent on CD40 priming 
by  activated  CD40+  T  cells.  Human  mono-
cyte-derived  DCs  infected  with  L. major  upregulate 
the  expression  of  costimulatory  molecules  like  B7-2 
and CD40 on their cell surface. However, the produc-
tion of IL-12p70 does not occur unless the cells have a 
secondary priming signal from the CD40:CD40L in-
teraction. The direct role of CD40:CD40L interaction 
in the T cell-DC interface was established by the reac-
tivation of T cells, isolated from L. major infected pa-
tients, by L. major infected DCs, either in the presence 
or absence of anti CD40L Ab [28]. IL-12 production is 
also  affected  during  defective  CD4+  T  cell  priming 
exemplified by low IL-12 production by splenocytes 
from CD40L -/- mice compared to wildtype (WT) mice 
[31].  
Activation of CD4+ T cells is important for pro-
duction of IFN-γ which in turn activates macrophages 
to produce IL-12, dictating a Th1 immune response 
[32]. In a study of L. major infection on CD40L-/- mice, 
the mice developed severe ulcerating lesions  which 
were  significantly  bigger  than  susceptible  BALB/c 
control mice unlike the study with L. major infected 
CD40-/- mice, where a lack of initial footpad swelling 
was observed [23, 31]. The inability of T cells to un-
dergo priming was evident by low IFN-γ levels in in 
vitro  cytokine  profiles  of  the  draining  lymph  node 
cells. The specific defect in the T cells from CD40L-/- 
mice was evident when peritoneal macrophages ob-
tained from CD40L-/- mice when treated with soluble 
CD40L and IFN- γ, showed IL-12 production [31].  
CD40:CD40L interaction has also been shown to 
be critical in clearing VL. CD40L-/- C57BL/6 mice did 
not develop granuloma at 4 weeks post infection and 
granulomas that developed at 8 weeks were heavily 
infiltrated with parasites. Treatment with agonist an-
ti-CD40  monoclonal  antibody  (MAb)  in  L. donovani 
infected  BALB/c  mice  resulted  in  greater  than  50% 
reduction in liver parasite burden, high serum IFN-γ 
activity  while  antimony  treatment  in  infected 
CD40L-/- mice, resulted in no disease resolution. This, 
along with the lack of granuloma formation points to 
insufficient  antigen  activated  CD4+  T  cell  and  DC 
development. Further, anti CD40 MAb treatment re-
sulted in development of mature granulomas; these 
were characterized by unique parasitized foci encased 
with  mononuclear  cells  (morphologically  lympho-
cytes)  which  was  not  visualized  in  the  IgG  treated 
control  mice  (both  infected  C57BL/6  and  BALB/c 
mice) [33]. 
IL-10 is an important cytokine that is implicated 
in  the  sustained  persistence  and  exacerbation  of 
leishmaniasis [34-36]. What makes the understanding 
of disease resolution complicated from the perspec-
tive of CD40 co-stimulation is the fact that both IL-12 
and  IL-10  are  produced  upon  CD40  receptor  en-
gagement [28, 37]. The balance between the two cyto-
kines can determine disease resolution or persistence 
in a given model of infection [38]. CD40 stimulation in 
macrophages causes IL-12 production via p38 MAP 
kinase pathway [39, 40]. CD40 primed macrophages 
can also produce IL-10 by ERK1/2 activation of the 
MAP kinase family [39, 41]. Interestingly, the strength 
of CD40 cross linking determines amount of IL-10 and 
IL-12 produced by macrophages, as shown previously 
[39].  Uninfected  macrophages  show  higher  produc-Int. J. Biol. Sci. 2011, 7 
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tion of IL-10 at CD40 Ab concentrations of 2µg/ml, 
peaking  at  4µg/ml  and  falling  at  about  8µg/ml. 
However, there is a steady increase of IL-12p40 levels 
from 2µg/ml to 16µg/ml concentrations of CD40 Ab. 
This indicates that at low CD40 cross linking, more 
IL-10  is  produced  while  higher  CD40  cross  linking 
shifts the balance towards IL-12 production in unin-
fected macrophages. However, surprisingly, this pat-
tern is not seen in macrophages infected with L. major. 
With  increasing  parasite  to  macrophage  ratio  at  an 
intermediate  concentration  of  CD40  Ab  (3µg/ml), 
there  is  increasing  production  of  IL-10  while  a 
downward  trend  for  IL-12  production  [39].  Apart 
from the strength of CD40 cross linking to provide 
host protective immune response, the relative expres-
sion  levels  of  CD40  also  play  a  role  in  modulating 
immune responses. Recent studies have shown that 
differential levels of CD40 expression on DCs can act 
to develop specific subsets of T cells. At lower CD40 
expression  levels,  as  seen  in  DCs  isolated  from 
CD40+/- background, there was selective development 
of regulatory T cells (Tregs) which dampen inflam-
matory responses. However, at higher expression of 
CD40,  which  is  seen  in  DCs  isolated  from  CD40+/+ 
background, there was development of effector T cells 
that  facilitated  parasite  clearance  and  reduced  sus-
ceptibility to L. donovani infection. These results indi-
cate that CD40 signaling does not contribute solely to 
proinflammatory  immune  processes  (like  T  cell 
priming,  macrophage  activation  and  IL-12  produc-
tion), but is also responsible for modulating immune 
responses  by  IL-10  production  and  Treg  cell  devel-
opment [42].  
Studies  have  also  shown  that  Leishmania  is  ac-
tively involved in elevating disease exacerbating cy-
tokine  levels  by  manipulating  CD40  signaling  cas-
cade.  This  is  seen  in  macrophages  infected  with  L. 
major  which  predominately  show  high  ERK1/2 
phosphorylation and thus high IL-10 production [39]. 
Other studies have shown that L. major causes deple-
tion of membrane cholesterol on macrophage surface 
and selective decrease in p38MAP kinase phosphor-
ylation  and  increase  in  ERK1/2  phosphorylation. 
Hence, this is an immune evasion strategy where L. 
major actively downregulates the production of IL-12 
in the macrophage and alters the CD 40 signalosome 
to  enhance  IL-10  production  and  thus  parasite  sur-
vival [43].  
The B7 family 
This family comprises of molecules of Ig super-
family  and  is  characterized  by  an  extracellular  IgV 
like and IgC like domains [10, 44]. B7 molecules are 
expressed by APCs such as DCs, macrophages, B cells 
and also T cells [45]. B7-2(CD86) is constitutively ex-
pressed and rapidly upregulated following activation 
while B7-1(CD80) is induced after B7-2 expression [44, 
46].  B7-1/B7-2  have  dual  specificity  for  receptors 
CD28  and  cytotoxic  T  lymphocyte  antigen-4 
(CTLA-4/CD152) on T cells. CD28 and CTLA-4 are 
also members of the Ig superfamily. The extracellular 
IgV  like  domain  on  CD28  and  CTLA-4  have  an 
MYPPPY motif on the complementarity determining 
region 3 (CDR3) like region. This motif is involved in 
binding to B7-1 and B7-2 [10, 47-49]. CD28 is constitu-
tively expressed by T cells while CTLA-4 is induced 
rapidly  by  activated  T  cells  [10,  44].  CTLA-4  has 
higher binding affinity to B7-1/B7-2 than CD28 [44]. 
These factors establish a hierarchy during T cell acti-
vation stages such that B7 signals via CD28 during the 
initial  stage  of  antigenic  stimulation.  The  activation 
then induces CTLA-4 expression that can suppress T 
cell activation and establishes immune homeostasis. 
The latter role of CTLA-4 is mediated perhaps by its 
ability to outcompete CD28 for binding and also by its 
ability to dampen major players of the CD28 signaling 
pathway [50].  
B7:CD28/CTLA-4 signal transduction 
Interaction between B7 and CD28 activates tyro-
sine phosphorylation of YMNM motif in the intracel-
lular signaling domain of CD28. This motif interacts 
with  phosphatidylinositol-3  kinase  (PI3K)  and  Grb2 
[51]. The downstream effects of this signaling, results 
in upregulation  of intrinsic survival and anti apop-
totic factor Bcl-XL [52, 53], stabilization and transcrip-
tion of IL-2 mRNA and progression of T cell into cell 
cycle.  CD28  signaling  is  thus  responsible  for  T  cell 
proliferation,  differentiation,  survival  and  IL-2  syn-
thesis [52]. 
CTLA-4 signal transduction on the other  hand 
recruits Src homology 2 domain containing phospha-
tase 2 (SHP-2) [51] which dampens the activating ef-
fects of CD28 perhaps via dephosphorylation of TCRζ 
[51, 54]. B7: CTLA-4 signaling is also associated with 
generation  of  indoleamine-2,3-dioxygenase  (IDO) 
from DCs triggered by IFN-γ. IDO degrades trypto-
phan into kynurenines and causes apoptosis of T cells 
[44, 55, 56]. CTLA-4 signal transduction has also been 
implicated  in  autocrine  induction  of  transforming 
growth factor β (TGFβ), an immunosuppressive cyto-
kine from T cells  [6]. The T cell inhibiting effect of 
CTLA-4 is likely due to CD28 signal usurping role of 
CTLA-4 by outcompeting with the ligand and also the 
inhibitory pathways activated by it [57]. 
The roles played by these molecules have been 
highlighted in a variety of studies. CTLA-4 deficient 
mice develop lymphoproliferative disorders and are Int. J. Biol. Sci. 2011, 7 
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highly susceptible to autoimmune disorders [50]. This 
highlights the crucial role of CTLA-4 in maintaining 
peripheral  immunity  and  tolerance.  CD28  blockade 
leads  to  prolonged  allograft  and  xenograft  survival 
[53]. Blocking of B7:CD28 pathway has been found to 
be beneficial in autoimmune disease, asthma, allergy 
and transplantation models [44, 47, 58]. CTLA-4 Ig a 
known inhibitor of this pathway has been tested in 
clinical  trials  for  treatment  of  rheumatoid  arthritis 
[59]. Blocking  of B7:CTLA-4 signaling  has been im-
plicated in enhancing tumor rejection [44, 56].  
Role of B7 co-stimulation in leishmaniasis 
Induction  of  either  Th1  or  Th2  phenotypes  is 
governed by a number of factors amongst which cy-
tokine milieu at the time of antigenic stimulation is 
one of the most critical [60]. A number of studies have 
indicated  that  co-stimulatory  molecules  B7-1/B7-2 
can differentially influence the development of Th1 or 
Th2 cells. An in vitro experimental allergic encepha-
lomyelitis model indicates a Th1 inducing role of B7-1 
and a Th2 inducing role of B7-2 [60]. B7-2 however 
was shown to have Th1 inducing role in non-obese 
diabetic mice model [61] and in murine allergy and 
helminthic  infections  it  was  found  to  be  associated 
with Th2 induction [62]. Studies in L. major CL impli-
cate B7-2 in development of Th2 pathway and hence 
susceptibility while B7-1 did not influence CL [63]. 
Use of CTLA-4 Ig, an antibody that binds with 
B7 ligands and essentially prevents B7:CD28/CTLA4 
pathway  or  administration  of  B7-2  MAb  has  been 
shown  to  negatively  affect  Th2  cell  development 
[63-65]. Both treatments led to reduction in parasite 
burden  in  otherwise  susceptible  BALB/c  mice.  The 
protective effects correlated with a decrease in IL-4 in 
CTLA4-Ig treatment while B7-2 MAb treatment also 
resulted in a significant decrease in IL-10 along with 
IL-4. These treatments, however, had no effect on cy-
tokine profiles of C57BL/6 mice infected in a similar 
manner though reduction in parasite load was evident 
[63, 64]. Treatment with B7-1 MAb also had no sig-
nificant effect thus eluding to a critical role of only 
B7-2 in Th2 induction in L. major infection [63, 65]. 
When L. major CL on CD28 gene deficient mice 
was studied, parasite burden and disease progression 
in the CD28-/- mice was comparable with that of sim-
ilarly  infected  WT  mice  in  BALB/c  strain  while 
CD28-/- C57BL/6 were able to heal lesion as well as 
their WT counterparts. The CD28-/- BALB/c mice in 
these experiments were fully able to mount a Th2 re-
sponse indicating that CD28 is not necessary for gen-
eration  of  Th2  response  [66].  This  experiment  used 
high infection dose model, and the ability to mount a 
Th2 response even in the absence of CD28 was seen to 
be  independent  of  CTLA-4  signal  transduction  as 
CD28-/- mice administered CTLA-4 Ig still mounted a 
Th2  response  [65].  Interestingly,  another  study  that 
compared CL in BALB/c CD28-/- and B7-1-/-/ B7-2-/- 
double knockout (KO) mice also resulted in dissimilar 
phenotypes. Unlike the CD28-/- or B7-1-/- mice which 
were  both  susceptible  to  L.  major,  the  B7-2-/-  and 
B7-1-/-/B7-2-/- mice were resistant to CL. These stud-
ies also highlighted a critical role of B7-2 in directing 
Th2 immune response in L. major CL as interpreted 
from  low  IL-4  levels  in  the  resistant  mice  [67].  The 
difference  in  the  phenotype  of  CD28-/-  mice  from 
B7-1-/-/B7-2-/-  mice  may  be  due  to  a  compensatory 
co-stimulatory pathway or B7 signaling via alternate 
ligands in the CD28-/- mice [65]. This difference may 
also be attributable to parasite dose, as a study using 
lower  parasite  inoculum  (750  promastigotes)  in  a 
similar  infection  study  was  shown  to  be  associated 
with resolution of CL by the CD28-/- mice in an IFN-γ 
dependent fashion [68]. 
Contrary  to  above  observations,  a  study  using 
anti CTLA-4 Ab was found to exaggerate the disease 
phenotype in L. major infected BALB/c mice concom-
itant with increased production of IL-4 and IL-13. An 
interesting aspect of this study was that even IL-4-/- 
BALB/c  mice  which  are  otherwise  resistant  to  CL 
developed lesions upon treatment with CTLA-4 Ab. 
The CTLA-4 Ab treated mice were also noted to pro-
duce  more  IL-13.  IL-13  is  capable  of  inhibiting  the 
activity  of iNOS. This study thus seems to indicate 
that other Th2 responses apart from IL-4 may also be 
at play [21]. 
In vitro studies using human cells where L. major 
infected macrophages were used to prime peripheral 
blood leukocytes indicated a decrease in IFN-γ and 
IL-5 upon blocking of the B7 pathway with CTLA4-Ig 
or anti CD86 [69]. In a similar experiment where pe-
ripheral  blood  mononuclear  cells  from  CL  patients 
were treated with Leishmania antigen, a decrease was 
noted in the production of TNF-α, IL-10 and IFN-γ on 
blocking B7-CD28/CTLA-4 using CTLA-4 Ig. While 
more studies are required in human model to better 
understand  the  modulatory  role  of  this  pathway,  it 
does seem this pathway especially B7-2 is important 
in shaping immune response to Leishmania [70]. 
Studies done in VL model have also suggested a 
modulatory role of B7 co-stimulation in the outcome 
of  infection.  BALB/c  mice  infected  with  L.  chagasi 
when treated with CTLA-4 MAb resulted not only in 
restoration  of  splenic  T  cell  proliferative  ability  but 
also led  to restoration  of IL-2 and IFN- γ synthesis 
comparable  with  the  WT  cells.  In  the  same  study, 
blockade of B7-1 but not B7-2 was shown to enhance T 
cell  response.  Further  CTLA-4  MAb  treatment  of Int. J. Biol. Sci. 2011, 7 
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parasite infected splenic macrophages led to signifi-
cant  clearance  of  parasite  when  activated  with  anti 
CD-3 in an in vitro study [9]. Anti CTLA-4 has also 
been shown to be effective in treatment of VL caused 
by  L.  donovani  [33,  71].  In  both  BALB/c  mice  and 
C57BL/6 mice infected with L. donovani, administra-
tion  of  anti  CTLA-4  MAb  led  to  better  granuloma 
formation [72]. In this study B7-2: CTLA-4 blockade 
led to clearance of parasite from liver [71] rather than 
B7-1: CTLA-4 as with the  L. chagasi model [9]. Anti 
CTLA-4 treatment in L. donovani infected mice model 
was further noted to enhance the anti leishmanicidal 
activity of sodium stibogluconate [33, 72]. 
While most of the studies on the role of B7 family 
co-stimulation have focused on B7-1 and B7-2, some 
studies  have  looked  at  other  B7  pathways  as  well. 
Inducible  co-stimulatory  protein  (ICOS),  a  CD28 
homolog, is induced in T cells upon TCR stimulation. 
ICOS signals via its ligand B7-H2/B7RP-1 [73, 74] and 
has  been  implicated  in  inducing  Th2  immune  re-
sponse  in  allergic  disease  models.  An  ICOS-/- 
129S4/SvJae mouse when infected with L. mexicana, 
another agent of CL, was found to produce delayed 
and  smaller  lesions  and  less  inflammation.  The  KO 
mice  were  also  defective  in  Ig  class  switching  and 
production of both IL-4 and IFN-γ was impaired in 
this system denoting ICOS is essential in L. mexicana 
CL for both Th1 and Th2 responses [73]. However, in 
the  L. major model of CL, antibody blockade of the 
receptor for ICOS or ICOS deficient mice led to better 
prognosis of infected BALB/c mice indicating a Th2 
inducing role of the pathway [74]. 
These studies account for  a definite role  of B7 
family of co-stimulatory molecules in modulating the 
outcome of leishmaniasis caused by various species of 
the  parasite.  The  blockade  of  certain  molecules  or 
their receptors presents an attractive tool to manage 
this disease. However, due to the complex nature of 
co-stimulation  and  the  obvious  differences  in  the 
pathway in different species calls for careful and de-
tailed study before these pathway can be manipulated 
for treatment. 
The OX40 family 
OX40, a member of Type I membrane glycopro-
tein  has  the  characteristic  4  cysteine  rich  domains 
(three complete and one truncated) of TNFR family of 
proteins. It is primarily present on activated T cells, 
including CD4+, CD8+, Th1, Th2, Th17 and Foxp3+ 
CD4+  Tregs  and  is  not  found  on  naïve  T  cells  or 
memory cells [75, 76]. OX40 ligand (OX40L) is a Type 
II membrane protein that consists of an extracellular 
domain  of  132  residues  with  no  site  for  proteolytic 
cleavage, indicating that it mainly exists in a mem-
brane bound form [75, 77]. The homotrimeric OX40L 
interacts  with  three  OX40  monomers  for  resultant 
biological effects [77]. OX40L is expressed mainly by 
professional APCs such as DCs, B cells, Langerhans 
cells  and  macrophages  upon  receiving  maturation 
signals from CD40, inflammatory cytokines like TSLP 
(thymic stromal lymphopoietin) and Toll-like recep-
tors (TLR2, 4 and 9). However, additional cell types 
like NK cells, vascular endothelial cells and smooth 
muscle cells can also express OX40L upon induction 
[75, 76]. 
Biological effects of OX40:OX40L interac-
tion 
While initial optimal activation of naïve T cells 
requires  co-stimulation  via  CD28:B7-1/B7-2, 
CD27:CD70 and CD40L:CD40, OX40:OX40L interac-
tion,  provides  effector  T  cells  with  signals  for  sus-
tained proliferation, memory CD4+ T cell generation 
and specific cytokine production [78]. Further, OX40L 
is expressed on mature DCs and OX40:OX40L inter-
action  enhances  production  of  cytokines  such  as 
TNF-α, IL-6, IL-1β and IL-12p40 [79]. The intracellular 
domain of OX40 binds to TNF-R associated factors, 
TRAF 2, TRAF 3 and TRAF5. A model of OX40 sig-
naling explains that recruitment of OX40 to lipid rafts 
occurs upon receptor engagement along with TRAF2, 
TRAF3and  TRAF5,  molecules  of  NF-kB  pathway 
(IKKα,  β),  p85  subunit  of  PI3K  and  Akt  which  can 
initiate  signaling  events  [76].  Also,  OX40  signaling 
helps  in  enhancing  expression  of  the  anti-apoptotic 
Bcl2  family  of  proteins  [76,  80].  OX40  signaling  is 
known to signal survivin, member of IAP (inhibitor of 
apoptosis)  family  of  proteins,  expression  in  late  G1 
phase of cell cycle which ultimately mediates T cell 
proliferation and clonal expansion [80].  
OX40:OX40L interactions in Leishmania 
models 
The role of OX40:OX40L interactions in Th cell 
differentiation has long been debated and it is now 
known that rather than playing a role in directly de-
termining  Th1/Th2  differentiation  phenotype, 
OX40:OX40L  interaction  helps  in  the  expansion  of 
ongoing immune responses whether they are benefi-
cial to the resolution of the disease or not [75, 76]. In a 
model  of VL in C57BL/6 mice, infected with  L. do-
novani,  the  efficacy  of  OX40L-Fc,  a  chimeric  fusion 
protein consisting of the extracellular OX40 binding 
domain of OX40L fused to immunoglobulin Fc region, 
administration was tested. It was noted that this ad-
ministration accelerated the development of mature 
granulomas  with  lower  amastigote  population.  A Int. J. Biol. Sci. 2011, 7 
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high  leishmanicidal  activity  with  the  promotion  of 
Th1 cytokine IFN- γ and IL-12p70 was also seen [72]. 
Interestingly, in a model of CL in Th2 background of 
BALB/c  mice,  administration  of  neutralizing  an-
ti-OX40 MAb, helped in reducing lesion development 
in these mice and reducing Th2 cytokine levels like 
IL-4, IL-10 and IL-13. However, no visible difference 
was seen in C57BL/6 mice with this treatment [81]. 
These results were further elucidated in a study with 
OX40L transgenic (Tg) mice. Apart from succumbing 
to  non-resolving  lesions,  the  OX40L  Tg  mice  also 
showed strong Th2 responses of their draining lymph 
node cells [82]. Taken together, these results suggest 
that  the  outcome  of  OX40:OX40L  interactions,  de-
pends  on  the  pre-existing  immune  reactions  in  the 
host and manipulating the model can yield different 
immune responses.  
Conclusion 
A  variety  of  co-stimulatory  pathways  contrib-
utes to diverse immune reaction against leishmaniasis 
with variation in response amongst different species 
of Leishmania. CD40:CD40L interaction helps in estab-
lishing a protective immune response by IL-12 pro-
duction,  macrophage  activation  and  CD4+  T  cell 
priming, while under certain conditions it promotes 
suppressive  immune  response  by  IL-10  production 
and  Treg  development.  B7-1/B7-2:CD28/CTLA-4 
signaling  seems  to  be  critical  for  Th2  immune  re-
sponse,  however  a  complex  relation  seems  to  exist 
according to the genetic background of the host, the 
infecting  dose  and  the  species  of  parasite. 
OX40:OX40L interaction mediates T cell proliferation 
and  clonal  expansion  following  an  established 
Th1/Th2 immune response and thus the outcome of 
this interaction depends on the pre-existing host im-
mune  response.  Due  to  the  obvious  importance  of 
co-stimulatory  pathways  in  leishmaniasis,  further 
studies  that  elucidate  the  complex  interactions  of 
co-stimulatory  pathways  will  yield  insights  into 
therapeutic strategies against Leishmania infection.  
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